# CRISPR Therapeutics

Source: https://onco.cc/companies/crispr-therapeutics/  
OnCo record `crispr-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CRISPR Therapeutics is the gene-editing company co-founded by Emmanuelle Charpentier that shares Casgevy with Vertex and is building off-the-shelf CAR-T cells such as CTX112 for lymphoma and autoimmune disease.

## Summary

CRISPR Therapeutics, headquartered in Zug with research in Boston, uses CRISPR/Cas9 to make gene-edited medicines. With Vertex it brought exagamglogene autotemcel (Casgevy) to approval for sickle cell disease and beta thalassaemia. In oncology it develops allogeneic CAR-T cells made from healthy donor T cells: CTX112 targets CD19 in B-cell malignancies and lupus, and CTX131 targets CD70 in solid tumours and haematological cancers. The company also has in vivo editing programmes for cardiovascular disease.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: CRISPR Therapeutics AG; NASDAQ:CRSP
- Tags: drug-maker
- HQ: Zug
- Type: cell-therapy
- Website: https://www.crisprtx.com/
- Ticker: NASDAQ:CRSP

## Sources

- Official website: https://www.crisprtx.com/

## Connected records

- drugs: [CTX112](https://onco.cc/drugs/ctx112/)

---
JSON: https://onco.cc/api/v1/entities/crispr-therapeutics.json